Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP549325.RATYejzhwEs9v07xvVi4ZGsPW-jDt9qBoz4F4rAaBS--Y130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP549325.RATYejzhwEs9v07xvVi4ZGsPW-jDt9qBoz4F4rAaBS--Y130_assertion type Assertion NP549325.RATYejzhwEs9v07xvVi4ZGsPW-jDt9qBoz4F4rAaBS--Y130_head.
- NP549325.RATYejzhwEs9v07xvVi4ZGsPW-jDt9qBoz4F4rAaBS--Y130_assertion description "[However, because Navitoclax has a low binding affinity to Mcl-1, anticancer activity by Navitoclax is often attenuated by the elevated expression of Mcl-1 in hepatocellular carcinoma (HCC) and other cancers, posing a serious problem for its potential clinical utilities.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP549325.RATYejzhwEs9v07xvVi4ZGsPW-jDt9qBoz4F4rAaBS--Y130_provenance.
- NP549325.RATYejzhwEs9v07xvVi4ZGsPW-jDt9qBoz4F4rAaBS--Y130_assertion evidence source_evidence_literature NP549325.RATYejzhwEs9v07xvVi4ZGsPW-jDt9qBoz4F4rAaBS--Y130_provenance.
- NP549325.RATYejzhwEs9v07xvVi4ZGsPW-jDt9qBoz4F4rAaBS--Y130_assertion SIO_000772 23611778 NP549325.RATYejzhwEs9v07xvVi4ZGsPW-jDt9qBoz4F4rAaBS--Y130_provenance.
- NP549325.RATYejzhwEs9v07xvVi4ZGsPW-jDt9qBoz4F4rAaBS--Y130_assertion wasDerivedFrom befree-20150227 NP549325.RATYejzhwEs9v07xvVi4ZGsPW-jDt9qBoz4F4rAaBS--Y130_provenance.
- NP549325.RATYejzhwEs9v07xvVi4ZGsPW-jDt9qBoz4F4rAaBS--Y130_assertion wasGeneratedBy ECO_0000203 NP549325.RATYejzhwEs9v07xvVi4ZGsPW-jDt9qBoz4F4rAaBS--Y130_provenance.